CWM
LGND icon

Congress Wealth Management’s Ligand Pharmaceuticals LGND Stock Holding History

Congress Wealth Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$10.7M Sell
94,417
-1,897
-2% -$203K 0.1% 232
2025
Q1 		$10.1M Buy
96,314
+1,979
+2% +$224K 0.12% 200
2024
Q4 		$10.1M Buy
94,335
+4,014
+4% +$454K 0.14% 199
2024
Q3 		$9.04M Buy
90,321
+2,071
+2% +$208K 0.12% 226
2024
Q2 		$7.44M Buy
+88,250
New +$7.02M 0.12% 206

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Congress Wealth Management's LGND Position: Q2 2025 in Review

Congress Wealth Management reduced its Ligand Pharmaceuticals (LGND) stake by 2% in Q2 2025, selling an estimated $203K and leaving 94,417 shares worth $10.7M. The position accounts for 0.1% of the portfolio, ranked #232.

Congress Wealth Management first reported a position in LGND in Q2 2024 and has held it in 5 quarters since. 271 funds tracked by Wall St. Rank hold LGND as of Q2 2025.

  • Congress Wealth Management held 94,417 shares of Ligand Pharmaceuticals worth $10.7M as of Q2 2025.
  • Congress Wealth Management sold 1,897 Ligand Pharmaceuticals shares in Q2 2025, an estimated $203K.
  • Ligand Pharmaceuticals made up 0.1% of Congress Wealth Management's portfolio in Q2 2025, its #232 holding.
  • Congress Wealth Management first reported a position in Ligand Pharmaceuticals in Q2 2024 and has held it in 5 quarters since.
  • 271 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2025.

Based on Congress Wealth Management's 13F filing for Q2 2025, filed 13 Aug 2025.